Amylyx Pharmaceuticals, Inc.
AMLX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | -$665 |
| % Growth | – | – | 100% | – |
| Cost of Goods Sold | $19,855 | $141 | $0 | $0 |
| Gross Profit | -$19,855 | -$141 | $0 | -$665 |
| % Margin | – | – | – | 100% |
| R&D Expenses | $19,855 | $27,076 | $22,119 | $22,892 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $16,172 | $15,640 | $15,684 | $17,097 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$19,855 | $0 | $0 | $0 |
| Operating Expenses | $16,172 | $42,716 | $37,803 | $39,989 |
| Operating Income | -$36,027 | -$42,857 | -$37,803 | -$40,654 |
| % Margin | – | – | – | 6,113.4% |
| Other Income/Exp. Net | $1,641 | $1,414 | $1,896 | $2,473 |
| Pre-Tax Income | -$34,386 | -$41,443 | -$35,907 | -$38,181 |
| Tax Expense | $0 | $0 | $0 | -$635 |
| Net Income | -$34,386 | -$41,443 | -$35,907 | -$37,546 |
| % Margin | – | – | – | 5,646% |
| EPS | -0.37 | -0.46 | -0.42 | -0.55 |
| % Growth | 19.6% | -9.5% | 23.6% | – |
| EPS Diluted | -0.37 | -0.46 | -0.42 | -0.55 |
| Weighted Avg Shares Out | 93,333 | 89,139 | 85,697 | 68,593 |
| Weighted Avg Shares Out Dil | 93,333 | 89,139 | 85,697 | 68,593 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,821 | $1,960 | $2,231 | $2,316 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $120 | $141 | $156 | $160 |
| EBITDA | -$34,266 | -$41,302 | -$37,647 | -$40,494 |
| % Margin | – | – | – | 6,089.3% |